Korean J Otorhinolaryngol-Head Neck Surg.  2007 Dec;50(12):1141-1148.

Clinical Significance in Expression of p53, Bcl-2, PCNA and VEGF in Head and Neck Squamous Cell Carcinoma: Relationships with Cisplatin Chemosensitivity and Prognosis

Affiliations
  • 1Department of Otorhinolaryngology, Pusan National University School of Medicine, Busan, Korea. wangsg@pusan.ac.kr

Abstract

BACKGROUND AND OBJECTIVES: Many researchers have attempted to correlate tumor marker expression with the response of chemoradiotherapy and prognosis of head and neck cancer. But no clear markers are available that can predict responses to treatment or survival in head and neck cancer. This study investigates the relationship between tumor marker expressions and prognosis.
SUBJECTS AND METHOD
Thirty-eight patients who received cisplatin and 5-fluorouracil (5-FU) chemotherapy for the treatment of head and neck cancer were enrolled in this study. Author evaluated the relationship between the response of chemotherapy and the immunohistochemical expression of p53, Bcl-2, VEGF, PCNA. The relationship between survival and tumor marker expression was evaluated in twenty five patients who received chemotherapy and radiotherapy.
RESULTS
Expression rates of p53, Bcl-2, VEGF, PCNA were 65%, 26%, 26%, 68%, respectively. Of the markers examined, while the expression of p53 was associated with chemosensitivity (p=0.02), other markers was not associated with chemosensitivity (p>0.05). The recurrent rate was 52%. T stage seemed to be associated with recurrence (p=0.07), tumor markers and other clinical parameters were not associated with recurrence (p>0.05). Five year survival rate was 60%. The primary site of tumor seemed to be associated with the overall survival rate of (p=0.07). Any other clinical characteristics and tumor markers were not associated with survival.
CONCLUSION
The expression of p53 may be a clinically useful predictor of chemosensitivity in this group of patients. Further studies using a larger group is needed to establish the relationship between tumor markers and prognosis of head neck cancer.

Keyword

Head and neck cancer; Cisplatin; Chemosensitivity; p53; Prognosis

MeSH Terms

Carcinoma, Squamous Cell*
Chemoradiotherapy
Cisplatin*
Drug Therapy
Fluorouracil
Head and Neck Neoplasms
Head*
Humans
Neck*
Prognosis*
Proliferating Cell Nuclear Antigen*
Radiotherapy
Recurrence
Survival Rate
Biomarkers, Tumor
Vascular Endothelial Growth Factor A*
Cisplatin
Fluorouracil
Proliferating Cell Nuclear Antigen
Vascular Endothelial Growth Factor A
Full Text Links
  • KJORL-HN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr